Erasca (ERAS) Stock Price

Erasca Price

NASDAQ·CLOSED
15.17
​
Market closed

The consensus 12-month price target for Erasca is 21.50 USD, about 41.7% above where the stock trades today. Of 16 analysts, 13 rate the stock a buy — an overall Buy consensus.

Erasca stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Erasca business model & stock analysis

Erasca Inc., based in San Diego, US, is a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers. The company operates with a pipeline of 12 programs, including five clinical-stage candidates such as naporafenib, an ATP-competitive pan-RAF inhibitor, and seven discovery-stage initiatives targeting key oncogenic drivers. With 103 employees, Erasca is listed on the stock market since July 15, 2021.

Frequently asked questions about Erasca

Analysts currently set an average price target of 22.50 USD for the Erasca stock (median: 21.50 USD), implying +44.1 % versus the latest price. The consensus is based on 16 analyst ratings.

16 analysts currently rate the Erasca stock: 13 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Erasca to generate revenue of 7.52 M USD and earnings per share of -0.97 USD.

Converted at the current exchange rate, the Erasca share trades at 13.56 EUR (15.17 USD).

The Erasca share (ERAS) is listed on 1 stock exchanges, including: NASDAQ (ERAS).

The expected revenue of Erasca is 7.52 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Erasca is -275.96 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Erasca is currently -15.59. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Erasca stock.

The price-to-sales ratio (P/S) of Erasca is currently 572.34. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Erasca stock.

The Eulerpool Quality Score for Erasca is 2/10.

The ISIN of Erasca is US29479A1088. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Erasca is ERAS. The ticker symbol is used to trade Erasca shares on the stock exchange.

Fair ValueTerminal
13.35 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website erasca.com
Currency
USD
Initial public offering
Jul 15, 2021
ISIN
US29479A1088
Cusip
29479A108
Market capitalization
4.30 B USDMid Cap
52-Week Range
PEG
2.31
P/E ratio
P/Ee 2026
-15.59
P/Ee 2027
-24.45
P/Ee 2028
-19.54
P/Ee 2029
-16.18
P/Ee 2030
-35.08
P/S
P/Se
572.34
EV/EBIT
—
P/B Ratio
13.23
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-38.30 %
Last updated Nov 11, 2026, 4:53 AM

Erasca Peer Group

Erasca Ticker

NASDAQ · ERAS

Erasca FIGI

ERAS:US · BBG00MTSR883ERAS:UA · BBG011M1RSR9ERAS:UC · BBG011M1RSS8ERAS:UN · BBG011M1RSV4ERAS:UP · BBG011M1RSW3ERAS:UB · BBG011M1RSY1ERAS:UM · BBG011M1RT06ERAS:UX · BBG011M1RT15ERAS:UD · BBG011M1RT60ERAS:UW · BBG011M1RT88ERAS:UF · BBG011M1RT97ERAS:VY · BBG011M1RTB4

All fundamentals and in-depth analysis of Erasca

Our stock analysis for Erasca stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Erasca. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.